AIkido Pharma Inc. (NASDAQ:AIKI) traded at $1.03 at close of the session on Monday, May 03, made an upward move of 1.98% on its previous day’s price.
Looking at the stock we see that its previous close was $1.01 and the beta (5Y monthly) reads 1.56 with the day’s price range being $0.9810 – 1.0300. The company has a trailing 12-month PE ratio of 0. In terms of its 52-week price range, AIKI has a high of $2.55 and a low of $0.47. The company’s stock has gained about -9.65% over that past 30 days.
On the other hand, looking at the outlook for the AIKI stock, short term indicators assign the stock an average of Hold, while medium term indicators assign it an average of Hold. Long term indicators on average place the stock in the category of 50% Buy.
Looking further, we note that the PEG ratio for the AIKI stock currently stands at 0, and the current price level is 3.05% off its SMA20 and -10.42% from its 50-day simple moving average. The RSI (14) is pointing at 48.55 while the volatility over the past week is 6.98% and jumps to 8.41% over the past one month. The beta value is 1.56, while the average true range (ATR) is currently pointing at 0.09. The average price target for the stock over the next 12 months is $1802.25, with the estimates having a low of $1802.25 and a high of $1802.25. These price ends are 174875.7% and +174875.7% off the current price level respectively, although investors could be excited at the prospect of a +174875.7% if the AIKI share price touches on the median price of $1802.25.
Let’s briefly compare AIkido Pharma Inc. (AIKI) stock to its peers. We find that current price change of +1.98% and +44.83% over the past 12 months for AIKI betters that of Bristol-Myers Squibb Company (BMY), which has seen its stock price fall -0.75% in the last trading session and was +2.65% over the last one year. Another of its peers Amgen Inc (AMGN) has climbed 2.1% previous session, and was +0.18% up over the past year, while Gilead Sciences Inc (GILD) was also up 1.98% in the last session, while its price remained in the green at 44.83% over the same period. AIkido Pharma Inc. has a P/E ratio of 0 compared to Bristol-Myers Squibb Company’s 0 and Amgen Inc’s 19.85. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial were at -0.72% and -0.54%, respectively, at close of the trading.
Coming back to AIkido Pharma Inc. (NASDAQ:AIKI), we note that the average 3-month trading volume was 19.44 Million, while that of the preceding 10-day period stands at 3.69 Million. Current shares outstanding are 88.91 Million.
According to data from Thomson Reuters, insiders hold 0.05% of the company’s shares while institutions hold 8.6%. The data shows that short shares as of April 14, 2021, stood at 964.2 Million at a short ratio of 0.11. This represents a 1.08% short interest in shares outstanding on April 14, 2021. Shares short rose in April from the previous month at 542.07 Million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock +17.92% up in year-to-date price movement.